REDWOOD CITY, Calif., Nov. 1, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today provided a business update and reported financial results for the three and nine months ended September 30, 2016.
Corporate Highlights
ARX-04 Clinical and Commercial Update:
During the third quarter of 2016, AcelRx presented the results of SAP302, the single-arm, open-label Phase 3 trial of ARX-04 (sufentanil sublingual tablet, 30 mcg) in patients who presented to the emergency room with moderate-to-severe acute pain associated with trauma or injury, at the Military Health System Research Symposium. Overall, the 76 adults treated with ARX-04 in this study experienced a 35% decrease, an overall reduction of 2.9 from a baseline of 8.1, in mean pain intensity at 60 minutes. Adverse events reported in the study were typical of opioid therapy, the most common of which were nausea, somnolence (sleepiness) and vomiting.
Results were also announced in the third quarter from SAP303, an open-label Phase 3 trial of ARX-04 in 140 adults who underwent short-stay, in-hospital surgeries associated with moderate-to-severe acute pain. Patients in this study were at least 40 years old and included patients with baseline renal and/or hepatic impairment. In SAP303, treatment with ARX-04 was associated with improvements in pain intensity as early as 30 minutes after the start of dosing and a 49% reduction in mean pain intensity during the first 2 hours. The most commonly reported adverse events were nausea and headache. Notably, there were no differences in adverse events between patients with normal and impaired liver or renal function.
Howie Rosen, chief executive officer, commented, “With clinical development of ARX-04 completed, we have been focused on completing the New Drug Application, which we expect to submit before the end of the year. In anticipation of achieving this very significant milestone, we are finalizing our commercial strategy, which currently has AcelRx launching ARX-04 into the emergency medicine market with our own sales force.”
Zalviso® U.S. and European Update:
In September, AcelRx also announced the initiation of IAP312, a Phase 3 trial of Zalviso (sufentanil sublingual tablet system) in approximately 315 hospitalized, post-operative patients who will use the Zalviso system to self-administer sufentanil sublingual tablets as needed for 24 to 72 hours to manage their moderate-to-severe acute pain. This study was designed with input from the U.S. Food and Drug Administration, and, in addition to safety and efficacy measures, will collect information on device usability, including any incidence of Zalviso’s failure to dispense medication as well as the incidence of misplaced or dropped tablets.
In Europe, AcelRx’s licensee, Grunenthal Group, continues its launch of Zalviso in additional hospitals and countries. Full commercial launch has begun in Germany, France and the UK; and a pilot launch program has commenced in Belgium, Italy, the Netherlands and Ireland. To date Zalviso has been used in 83 hospitals, in seven countries.
Third Quarter 2016 Financial Results
Net loss for the third quarter of 2016 was $11.4 million, or $0.25 basic and diluted net loss per share, compared to net income of $5.1 million, or $0.11 basic and diluted net income per share for the third quarter of 2015. The net income in the third quarter of 2015 was primarily due to revenue recognized from the milestone payment received under the Grunenthal agreement related to the approval of the Marketing Authorization Application in the EU. Common shares used in calculating net (loss) income per share were 45.3 million for basic and diluted earnings per share (EPS) in the third quarter of 2016, compared to 44.4 million for basic EPS and 45.0 million for diluted EPS in the third quarter of 2015.
During the third quarter of 2016, AcelRx recognized revenue of $1.6 million under the collaboration agreement with Grunenthal and $1.8 million related to work performed under the Department of Defense (DoD) contract for ARX-04. This compares to $13.9 million in revenue recognized under the collaboration agreement with Grunenthal and $1.5 million in revenue recognized related to the DoD contract during the third quarter of 2015. AcelRx anticipates royalty revenue from Grunenthal will continue to be modest in 2016 and into 2017 as they continue their pilot programs and commercial expansion in various countries.
Operating costs and expenses during the third quarter of 2016 included cost of goods sold of $2.6 million. Research and development expenses for the third quarter of 2016 were $4.6 million, as compared to $5.4 million for the third quarter of 2015. The $0.8 million decrease in research and development expenses was primarily due to a reduction in overhead costs, predominantly as a result of the allocation of certain personnel and related expenses to cost of goods sold.
General and administrative expenses were $4.1 million during the third quarter of 2016, as compared to $2.9 million for the third quarter of 2015. The $1.2 million increase in general and administrative expenses during the three months ended September 30, 2016, as compared to the three months ended September 30, 2015, was primarily due to ARX-04-related market research activities in preparation for the anticipated commercial launch of ARX-04.
Total other expenses increased from $1.3 million in the third quarter of 2015 to $3.5 million in the third quarter of 2016, primarily as a result of non-cash interest expense on the royalty monetization.
The royalty monetization resulted in a taxable gain of more than $60.0 million in the third quarter of 2015, the majority of which was offset with net operating loss carryforwards; however, AcelRx was subject to U.S. federal alternative minimum taxes in 2015, as reflected in its provision for income taxes in the third quarter of 2015.
Year-to-Date Financial Results
For the nine months ended September 30, 2016, AcelRx reported a net loss of $33.5 million, or $0.74 basic and diluted net loss per share, as compared to a net loss of $13.9 million, or $0.31 basic net loss per share and $0.37 diluted net loss per share for the same period in 2015. Common shares used in calculating earnings per share were 45.3 million for basic and diluted net loss in the nine months ended September 30, 2016, as compared to 44.2 million for basic EPS and 44.4 million for diluted EPS in the nine months ended September 30, 2015.
AcelRx recognized revenue of $4.7 million under the collaboration agreement with Grunenthal and $6.2 million related to work performed under the DoD contract for ARX-04 in the nine months ended September 30, 2016. This compares to $14.5 million in revenue recognized under the collaboration agreement with Grunenthal and $3.0 million in revenue related to the DoD contract recognized in the nine months ended September 30, 2015.
Operating costs and expenses during the nine months ended September 30, 2016 included cost of goods sold of $9.2 million. Research and development, and general and administrative expenses during the nine months ended September 30, 2016 were $15.1 million and $11.5 million, respectively. These compare to $19.0 million in research and development expenses and $10.2 million in general and administrative expenses in the first nine months of last year. The $3.9 million decrease in research and development expenses was primarily attributable to a reduction in overhead costs, predominantly as a result of allocation of certain research and development personnel and related expenses to cost of goods sold, while the increase in general and administrative expenses of $1.3 million was primarily due to ARX-04-related market research activities.
Total other expense was $8.7 million during the nine months ended September 30, 2016, as compared to $0.7 million during the nine months ended September 30, 2015. The difference was primarily a result of non-cash interest expense on the royalty monetization and the revaluation of the PIPE warrants issued in June 2012.
As of September 30, 2016, AcelRx had cash, cash equivalents and investments of $92.5 million, compared to $113.5 million at December 31, 2015. The decrease was primarily attributable to cash used in operating activities. AcelRx anticipates the cash balance will be approximately $75 million at the end of 2016.
On September 30, 2016, AcelRx amended the terms of the debt payable to Hercules Growth Technology. The amendment extends the interest only period by six months through April 1, 2017. Contingent upon FDA acceptance of the NDA for ARX-04 prior to April 1, 2017, Hercules has agreed to refinance the loan into a 36-month term note with an additional six month interest only period. In addition, subject to the achievement of certain milestones, AcelRx may be able extend the repayment period up to 48 months and extend the interest only period by up to a total of 18 months. Further, under certain conditions, AcelRx may be able to borrow an additional $10 million. In the short term, the additional interest only period will reduce cash used for financing activities over the next six months. In the long term, the potential to refinance the principal amount of $20.4 million and to obtain an additional $10 million will give AcelRx added flexibility to fund the anticipated launch of ARX-04.
Conference Call
AcelRx will conduct a conference call and webcast today, November 1, 2016 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss these financial results and business updates. To listen to the conference call, dial in approximately ten minutes before the scheduled call 1-866-361-2335 for domestic callers, 1-855-669-9657 for Canadian callers, or 1-412-902-4204 for international callers.
To read full press release, please click here.
